A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus

A 1 Month, Open-Label Inpatient, Randomized Cross-Over Trial Assessing The Impact Of Dry Powder Inhaled Insulin (Exubera) On 24-Hour Glycemic Control Compared To Insulin Glargine (Lantus) In Patients With Type 2 Diabetes Mellitus Who Are Poorly Controlled On A Combination Of Two Oral Agents

To compare short-term efficacy and safety of Exubera vs Lantus in patients with type 2 diabetes mellitus

Inclusion Criteria:

• Diabetes mellitus Type 2

Exclusion Criteria:

• Severe Asthma, severe COPD
• Smoking